Sitagliptin phosphate ine(Oxedrine) 1'-biphenyl]-4-yl)methyl)benzenesulfonamide

1'-biphenyl]-4-yl)methyl)benzenesulfonamide

Nevanac D5

3 L/kg in rats

Ca/c2*1-3-5-11(24)22-16-13-17(20-8-19-16)23(9-21-13)18-15(30-12(25)6-4-2)14-10(29-18)7-28-32(26

Sitagliptin phosphate ine(Oxedrine) 1'-biphenyl]-4-yl)methyl)benzenesulfonamideSitagliptin (INN; previously identified as MK 0431 and sold under the trade name Januvia) is an oral antihyperglycemic (anti diabetic drug) of the dipeptidyl peptidase 4 (DPP 4) inhibitor class. It was developed and is marketed by Merck & Co. This enzyme inhibiting drug is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for treatment of diabetes mellitus type 2. The benefit of